Literature DB >> 23494279

[Grey zone lymphomas: limitations of the classification of aggressive B-cell lymphomas].

M M Ott1, H Horn, A Rosenwald, G Ott.   

Abstract

Grey zone lymphomas are lymphatic tumors that cannot be assigned to a defined lymphoma entity due to morphological, clinical or genetic reasons. As a defining criterion they present with features of two overlapping entities or features that are intermediate. Such lymphomas may represent a grey zone in the differentiation between indolent and aggressive lymphomas. Often they may show morphological features of one entity but be more related to another entity with respect to the immunophenotype and/or genetic constitution, such as lymphomas in the grey zone between primary mediastinal large B-cell lymphoma and primary nodal diffuse large B-cell lymphoma. The B-cell lymphoma, unclassified, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma has recently been recognized as a provisional category in the updated WHO 2008 classification of malignant lymphomas. This corresponds to a practical lymphoma category that obviously contains several entities with a Burkitt-like appearance and aggressive clinical behavior. Genetically, tumors in this category are frequently characterized by an atypical MYC translocation and complex karyotypic alterations. As yet, no adequate therapy concept exists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23494279     DOI: 10.1007/s00292-013-1745-6

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

1.  B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors:  Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

2.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Authors:  Shaoying Li; Pei Lin; Luis E Fayad; Patrick A Lennon; Roberto N Miranda; C Cameron Yin; E Lin; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2011-10-14       Impact factor: 7.842

3.  Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.

Authors:  Rebecca F McClure; Ellen D Remstein; William R Macon; Gordon W Dewald; Thomas M Habermann; Antje Hoering; Paul J Kurtin
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

4.  Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.

Authors:  Itziar Salaverria; Claudia Philipp; Ilske Oschlies; Christian W Kohler; Markus Kreuz; Monika Szczepanowski; Birgit Burkhardt; Heiko Trautmann; Stefan Gesk; Miroslaw Andrusiewicz; Hilmar Berger; Miriam Fey; Lana Harder; Dirk Hasenclever; Michael Hummel; Markus Loeffler; Friederike Mahn; Idoia Martin-Guerrero; Shoji Pellissery; Christiane Pott; Michael Pfreundschuh; Alfred Reiter; Julia Richter; Maciej Rosolowski; Carsten Schwaenen; Harald Stein; Lorenz Trümper; Swen Wessendorf; Rainer Spang; Ralf Küppers; Wolfram Klapper; Reiner Siebert
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

5.  Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma.

Authors:  D De Jong; B M Voetdijk; G C Beverstock; G J van Ommen; R Willemze; P M Kluin
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

6.  Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma.

Authors:  Christiane Copie-Bergman; Marie-Laure Boulland; Catherine Dehoulle; Peter Möller; Jean-Pierre Farcet; Martin J S Dyer; Corinne Haioun; Paul-Henri Roméo; Philippe Gaulard; Karen Leroy
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

7.  Cytomorphologic spectrum of small lymphocytic lymphoma in patients with an accelerated clinical course.

Authors:  Hyung Ju C Shin; Nancy P Caraway; Ruth L Katz
Journal:  Cancer       Date:  2003-10-25       Impact factor: 6.860

Review 8.  Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma).

Authors:  T Rüdiger; E S Jaffe; G Delsol; C deWolf-Peeters; R D Gascoyne; A Georgii; N L Harris; M E Kadin; K A MacLennan; S Poppema; H Stein; L E Weiss; H K Müller-Hermelink
Journal:  Ann Oncol       Date:  1998       Impact factor: 32.976

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  1 in total

1.  EBV-Positive Grey Zone Lymphoma in an HIV Infected Man from Kampala, Uganda: Case Report.

Authors:  Lynette K Tumwine; Jackson Orem; Leona W Ayers
Journal:  Int J Med Pharm Case Reports       Date:  2014-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.